Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed ...

(RTTNews) - Lupin (LUPIN) has received approval from the FDA for its Abbreviated New Drug Application for Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and ...

NAPLES, Fla., Sept. 10, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval ...

BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone ...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ...

Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator for its generic version of risperidone for extended-release injectable suspension, used in the treatment ...

Many nurse leaders expressed surprise that the National Council Licensure Examination pass rate declined earlier this year, but most said the one-year drop is not cause for concern. In the first ...

RUSSELLVILLE, Ark. (KATV) — Arkansas Tech University in Russellville and Ozark is celebrating a significant milestone for its nursing program's performance on their NXLEX exam taken during the 2024-25 ...

Skipping daily pills is a common problem in schizophrenia care. A new study in the US tested a once-weekly oral version of risperidone. The results show that the drug remained at therapeutic levels ...

The National Council Licensure Examination pass rate for registered nurses dropped to 71.6% in the first quarter of 2025, down from 79.1% in the same period in 2024. The decline affected U.S.-educated ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...